Elevation of serum stem-cell factor in postoperative biliary atresia

Area of Science:

• Pediatric Gastroenterology
• Hepatology
• Fibrosis Research

Background:

• Biliary atresia (BA) is a leading cause of neonatal cholestasis.
• Stem cell factor (SCF) is linked to fibrosis in various conditions.
• The role of SCF in BA pathogenesis requires investigation.

Purpose of the Study:

• To investigate the role of stem cell factor (SCF) in pediatric patients with biliary atresia (BA).
• To determine if SCF levels correlate with disease severity and complications in BA.

Main Methods:

• Serum SCF levels were measured using ELISA in 57 pediatric BA patients post-Kasai operation and 30 healthy controls.
• Patients were stratified by total bilirubin and alanine aminotransferase (ALT) levels.
• Correlation with portal hypertension (PH) was assessed.

Main Results:

• BA patients exhibited significantly higher serum SCF levels than controls (748.3 vs 582.2 pg/mL).
• Elevated SCF was associated with higher ALT levels (indicating greater hepatic injury) and the presence of portal hypertension (PH).
• SCF levels were significantly higher in BA patients with PH (810.0 pg/mL) compared to those without (634.1 pg/mL).

Conclusions:

• Elevated serum SCF levels are characteristic of biliary atresia (BA) patients.
• SCF elevation is associated with increased hepatic injury and portal hypertension in BA.
• SCF may be a key factor in the development of hepatic fibrosis following the Kasai procedure for BA.